ArticleCancer2011

Phase 1 study of arsenic trioxide, high-dose cytarabine, and idarubicin to down-regulate constitutive signal transducer and activator of transcription 3 activity in patients aged <60 years with acute myeloid leukemia.

Meir Wetzler et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.